Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 33 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

C-2581 Cabazitaxel, >99%       Prices Reduced (May 2013)      NEW!

Synonyms:  [RPR-116258] [Taxoid XRP6258] [TXD-258] [XRP-6258] [RPR 116258] [RPR116258] [NSC-105823] [TXD 258] [TXD258] [XRP 6258] [XRP6258]
Related Terms:  [Jevtana]

M.W. 835.93

C45H57NO14

[183133-96-2]

M.I. 14:  10493

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 100 mg/mL; soluble in ethanol at 50 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-2 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Cabazitaxel, also known as XRP-6258, is a second-generation semi-synthetic derivative of paclitaxel, a natural taxoid microtubule inhibitor.  Paller, C.J. and Antonarakis, E.S.  "Cabazitaxel:  a novel second-line treatment for metastatic castration-resistant prostate cancer."  Drug Des. Devel. Ther. 5:  117-124 (2011).

• In preclinical studies, cabazitaxel was shown to have antitumor activity in a variety of docetaxel-refractory in vitro and in vivo models.  Bissery, M-C., et al.  "Preclinical evaluation of TXD258, a new taxoid."  Proceedings of the American Association for Cancer Research  Abstract 411364 (2000).  Vrignaud, P., et al.  "In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts."  Proceedings of the American Association for Cancer Research  Abstract 411365 (2000).

• 755 participants with metastatic castration-resistant prostate cancer who had received previous hormone therapy were treated with prednisone daily, and were randomly allocated to treatment groups (377 mitoxantrone and 378 cabazitaxel).  Median survival was 15.1 months in the cabazitaxel group and 12.7 months in the mitoxantrone group.  Median progression-free survival was 2.8 months in the cabazitaxel group and 1.4 months in the mitoxantrone group.  de Bono, J.S., et al.  "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:  a randomised open-label trial."  Lancet 376:  1147-1154 (2010).

• When compared with docetaxel and paclitaxel, cabazitaxel was reported to have poor affinity for the ATP-dependent drug efflux pump, P-glycoprotein 1 (P-gp), and greater penetration of the blood-brain barrier.  Mita, A.C., et al.  "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors."  Clin. Cancer Res. 15:  723-730 (2009).

• Brain uptake of cabazitaxel was increased when concentrations exceeded 11 µM and the saturation was found to be at 13 µM, suggesting the role of a critical transporter (that is, P-gp) in transporting cabazitaxel across the blood-brain barrier upon a certain threshold.  Cisternino, S., et al.  "Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats."  Br. J. Pharmacol. 138:  1367-1375 (2003).

• Cabazitaxel is the active ingredient in the drug product sold under the trade name Jevtana®.  This drug is currently approved in at least one country for use in patients with hormone-refractory metastatic prostate cancer.  NOTE:  THE CABAZITAXEL RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT JEVTANA®, AND IS NOT FOR HUMAN USE.

• Another CAS number previously assigned to cabazitaxel, namely 890654-44-1, has been deleted by CAS and is no longer in use.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, MedKoo BioSciences - website - Apr 2013, Medchem Express - website - Jan 2013, ChemScene - website - Jan 2013.